Fox Run Management L.L.C. Buys Shares of 6,071 Harmony Biosciences Holdings, Inc. $HRMY

Fox Run Management L.L.C. purchased a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the first quarter, according to its most recent filing with the SEC. The firm purchased 6,071 shares of the company’s stock, valued at approximately $201,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new position in Harmony Biosciences in the 1st quarter valued at approximately $57,000. HighTower Advisors LLC boosted its position in Harmony Biosciences by 73.2% during the first quarter. HighTower Advisors LLC now owns 19,748 shares of the company’s stock worth $655,000 after purchasing an additional 8,347 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in Harmony Biosciences by 27.1% in the first quarter. Public Sector Pension Investment Board now owns 121,154 shares of the company’s stock valued at $4,021,000 after purchasing an additional 25,802 shares during the last quarter. Nuveen LLC purchased a new position in shares of Harmony Biosciences in the first quarter valued at $3,805,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Harmony Biosciences during the 1st quarter worth $3,791,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Wall Street Analysts Forecast Growth

HRMY has been the topic of a number of research reports. Truist Financial initiated coverage on shares of Harmony Biosciences in a research note on Monday, July 21st. They issued a “buy” rating and a $48.00 price objective on the stock. UBS Group reduced their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Monday, April 28th. Oppenheimer began coverage on shares of Harmony Biosciences in a research report on Monday, June 2nd. They issued an “outperform” rating and a $61.00 price target on the stock. Mizuho raised their price objective on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an “outperform” rating in a research note on Thursday, May 15th. Finally, Wall Street Zen lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $51.00.

Harmony Biosciences Price Performance

NASDAQ:HRMY opened at $36.63 on Thursday. Harmony Biosciences Holdings, Inc. has a 12-month low of $26.47 and a 12-month high of $41.61. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of 11.82, a price-to-earnings-growth ratio of 0.43 and a beta of 0.84. The company’s 50-day moving average is $34.30 and its two-hundred day moving average is $33.71. The company has a current ratio of 3.84, a quick ratio of 3.80 and a debt-to-equity ratio of 0.20.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). The firm had revenue of $200.49 million for the quarter, compared to analysts’ expectations of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The business’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.05 earnings per share. Harmony Biosciences has set its FY 2025 guidance at EPS. Research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.